Table 2 Univariate and multivariate analysis of prognostic factors for overall survival in LUAD patients
From: MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells
| Â | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
HR | p value | 95% CI | HR | p value | 95% CI | |
MAGE-A1 expression | ||||||
 High versus low | 1.78 | 0.022* | 1.09–2.93 | 1.58 | 0.087 | 0.93–2.68 |
Gender | ||||||
 Male versus female | 1.38 | 0.183 | 0.86–2.20 |  |  |  |
Age | ||||||
 ≥ 60 years versus < 60 years | 0.96 | 0.861 | 0.59–1.55 |  |  |  |
Tumor diameter | ||||||
 ≥ 3 cm versus < 3 cm | 1.54 | 0.090 | 0.93–2.55 |  |  |  |
Pathological grade | ||||||
 Grade I–II versus grade III | 0.88 | 0.633 | 0.53–1.47 |  |  |  |
Lymph node metastasis | ||||||
 Positive versus negative | 2.47 | 0.001* | 1.49–4.09 | 1.02 | 0.950 | 0.44–2.42 |
T status | ||||||
 T1–T2 versus T3–T4 | 0.71 | 0.196 | 0.42–1.20 |  |  |  |
N status | ||||||
 Positive versus negative | 2.11 | 0.002* | 1.31–3.41 | 1.42 | 0.265 | 0.77–2.65 |
M status | ||||||
 Positive versus negative | 1.09 | 0.930 | 0.15–7.90 |  |  |  |
TNM stage | ||||||
 Stage I–II versus stage III–IV | 0.36 | 0.001* | 0.21–0.59 | 0.45 | 0.029* | 0.22–0.92 |